Oragenics Inc. & Aragen Bioscience Enter Agreement to Accelerate Development of TerraCoV2, a SARS-CoV-2 (COVID 19) Vaccine Ca...
May 19 2020 - 8:01AM
Business Wire
Oragenics, Inc. (NYSE American: OGEN), (the “Company” or
“Oragenics”), today announced, that through its wholly-owned
subsidiary, Noachis Terra, it has entered into an agreement with
Aragen Bioscience, a leading contract research organization focused
on accelerating pre-clinical biologics product development, to
advance TerraCov2 the Company’s SARS CoV-2 vaccine candidate. Under
the terms of the agreement, Aragen will provide cell line
development services to Oragenics to aid in the development of
Oragenics' TerraCoV2, which could provide specific immunity from
the novel coronavirus (“SARS-CoV-2”), the root cause of coronavirus
disease 2019 (“COVID-19”).
“Developing a variety of vaccine alternatives is critical to
bringing the SARS-Cov-2 pandemic under control. Utilizing the
technology created at NIH with Aragen’s pre-clinical development
capabilities will help us accelerate the development of the
TerraCov2 vaccine candidate. We believe the relationship between
the companies will result in advancement of the vaccine candidate
into the clinic as rapidly as possible,” said Alan Joslyn, Ph.D.,
President and CEO of Oragenics.
"We're delighted to initiate this project with Oragenics. Our
hope is that the combined efforts of Oragenics and Aragen can
accelerate TerraCoV2 development and provide a vital response to
COVID-19 and the devastating pandemic it has caused," said Axel
Schleyer, CEO of Aragen.
About Oragenics, Inc.
Oragenics, Inc. is focused on the creation of the TerraCoV2
immunization product candidate to combat the novel coronavirus
pandemic and the further development of effective treatments for
novel antibiotics against infectious disease and oral mucositis.
Through Noachis Terra, a wholly-owned subsidiary of Oragenics, the
Company is dedicated to the development and commercialization of a
vaccine candidate providing specific immunity from the novel
coronavirus, SARS-CoV-2, which causes COVID-19. The TerraCoV2
immunization leverages coronavirus spike protein research conducted
by the National Institute of Health, which issued a worldwide,
nonexclusive intellectual property license to Noachis Terra. In
addition, Oragenics also has two exclusive worldwide channel
collaborations, one with Precigen, Inc.’s subsidiaries relating to
the treatment of oral mucositis and the other with ILH Holdings,
Inc., relating to the development of novel antibiotics.
For more information about Oragenics, please visit
www.oragenics.com.
About Aragen Bioscience, Inc.
Aragen Bioscience, Inc., a wholly owned subsidiary of GVK BIO,
is a leading contract research organization based in the San
Francisco Bay Area. Aragen Bioscience offers a diverse set of in
vitro and in vivo services for the discovery, production,
characterization, activity and efficacy assessment and development
of biologic and diagnostic products. www.aragenbio.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200519005557/en/
Oragenics Contacts: Corporate: Michael Sullivan,
813-286-7900 Chief Financial Officer msullivan@oragenics.com
or Investors: John Marco Managing Director CORE IR
516-222-2560 johnm@coreir.com
Media: Jules Abraham CORE IR 917-885-7378
julesa@coreir.com
Aragen Bioscience Inc. Contact: Alexa Martinez Aragen
Bioscience, Inc. 408-201-3547 amartinez@aragenbio.com
Oragenics (AMEX:OGEN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Oragenics (AMEX:OGEN)
Historical Stock Chart
From Sep 2023 to Sep 2024